Condition category
Nutritional, Metabolic, Endocrine
Date applied
12/12/2007
Date assigned
25/01/2008
Last edited
15/09/2008
Prospective/Retrospective
Prospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Prof Michael Ranke

ORCID ID

Contact details

University Children's Hospital
Hoppe-Seyler-Strasse 1
Tuebingen
72076
Germany

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Investigation of overweight/adipose children and adolescents who face a high risk of insulin resistance: dietary intervention, exercise treatment and pre- and post-treatment status in the DISKUS study

Acronym

DISKUS study

Study hypothesis

The number of overweight children has risen staggeringly in Germany. Overweightness is associated with the metabolic syndrome and, by extension, with a high risk of cardiovascular morbidity and mortality. Up to now, attempts to treat children and adolescents have basically been limited to interventions targeting lifestyle. They have often not produced lasting effects, neither is it clear why these endeavours are shortlived. Our approach in attempting to clarify this issue is to undertake a comprehensive investigation of children and adolescents who face a high risk of the metabolic syndrome.

Ethics approval

Ethics approval received from the Ethics Committee of the University of Tuebingen on the 13th June 2007 (ref: 130/2007BO1).

Study design

Our study is a prospective, controlled, open, non-randomised investigation.

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Childhood obesity, metabolic syndrome

Intervention

Schematic diagram of the trial design (intervention group):
Preliminary examination: Presentation and examination at the Hospital for Children and Adolescent Medicine (one half-day visit) and at the Department of Sports Medicine (one half-day visit), including counselling by a sports medicine clinician. Sub-group: Additional investigations in 30 randomly-chosen patients: Mental Rotations Test (MRT), eye-tracking.
Months 1 - 6: Two nutritional counselling sessions focusing on the subjects of food and beverage choices, implementation in daily life. Physical activity and exercise at home (involving family, friends, recreational centre/sports club) as recommended by the sports medicine clinician.
Month 6: First interim examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol and the physical activity log book, followed by counselling. Sub-group (n = 30): Additional investigations comprise MRT and eye-tracking.
Months 7 - 12: Nutritional counselling session and/or further sports medicine instruction if required for exercise at home (involving family, friends, recreational centre/sports club) as recommended by the sports medicine clinician.
Month 12: Second interim examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol and the physical activity log book, followed by counselling.
Months 12 - 24: Observational phase: the intervention is implemented independently by the volunteer.
Month 24: Final examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol and the physical activity log book, followed by counselling.

Schematic diagram of the trial design (control group):
Preliminary examination: Presentation and examination at the Hospital for Children and Adolescent Medicine (one half-day visit).
Months 1 - 6: One nutritional counselling session focusing on the subjects of food and beverage choices, implementation in daily life.
Month 6: First interim examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol.
Months 7 - 12: Nutritional counselling session if required.
Month 12: Second interim examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol.
Months 12 - 24: Observational phase: the intervention is implemented independently by the volunteer.
Month 24: Final examination (same as first visit). Visit additionally includes the analysis of a four-day eating protocol.

Intervention type

Other

Phase

Not Specified

Drug names

Primary outcome measures

1. Significant yearly changes in the BMI (Standard Deviation Score [SDS])
2. Significant yearly changes in the level of fasting insulin (HOmeostasis Model Assessment of Insulin Resistance [HOMA-IR])

Outcomes measured at baseline and months 6, 12 and 24.

Secondary outcome measures

1. Improvements in physical fitness:
1.1. Ventilatory threshold
1.2. Period of total load
1.3. Subjective fatigue
1.4. Maximum heart rate
1.5. Watt-max test
1.6. Oxygen uptake
2. Lowering of the systolic/diastolic blood pressure to below the 95th centile
3. Improvements in the levels of High Density Lipoprotein (HDL) cholesterol, lowering of levels triglyceride levels
4. Reduction or reversal of pathological status of thickness and proportion of abdominal fat/skinfold thickness
5. Boost in general vigour
6. Improvement of well-being and mood, enhancement of health-related quality of life

Outcomes measured at baseline and months 6, 12 and 24.

Overall trial start date

01/02/2008

Overall trial end date

01/08/2010

Reason abandoned

Eligibility

Participant inclusion criteria

1. Overweight (Body Mass Index [BMI] greater than 90th centile) or obese (BMI greater than 97th centile)
2. Children and adolescents between the ages of 6 and 18 years
3. One or more of the following criterias:
3.1. Extreme obesity (BMI greater than 99.5 centile of age- and sex-matched references)
3.2. First-degree relative with type 2 diabetes/diabetes during pregnancy or two grandparents with type 2 diabetes
3.3. Neonatal size either small or large for gestational age (birth weight or birth length less than 5th/greater than 95th centile)
3.4. Acanthosis nigricans
3.5. Polycystic ovary syndrome
3.6. Children and adolescents with established glucose tolerance impairment, abnormal levels of fasting glucose, type 2 diabetes

Participant type

Patient

Age group

Child

Gender

Both

Target number of participants

Study group: n = 100; control group: n = 50

Participant exclusion criteria

1. Type 1 diabetes
2. Eating disorder
3. Pregnancy
4. Neoplasm or severe systemic disease
5. Cardiovascular disease
6. Mental retardation
7. Mental health problem

Recruitment start date

01/02/2008

Recruitment end date

01/08/2010

Locations

Countries of recruitment

Germany

Trial participating centre

University Children's Hospital
Tuebingen
72076
Germany

Sponsor information

Organisation

University Children's Hospital of Tuebingen (Germany) - Section of Pediatric Endocrinology

Sponsor details

c/o Michael B. Ranke
M.D.
Hoppe-Seyler-Strasse 1
Tuebingen
72076
Germany

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Government

Funder name

German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) - an application for a Research Grant has been submitted

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes